Latest liver cancer Stories

Bel Marra Health Reports on New Research: The Value of Liver Cancer Screening in Patients with Alcoholic Cirrhosis is Questionable

2013-04-06 23:02:34

Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, is reporting on new research that says the value of liver cancer screening in patients with alcoholic cirrhosis might be questionable. Toronto, ON (PRWEB) April 06, 2013 Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, is reporting on new research that says the value of liver cancer screening in patients with alcoholic cirrhosis might...

Celsion Corporation Provides an Update Regarding ThermoDox® Agreements with Zhejiang HISUN Pharmaceutical Company for China

2013-02-05 20:21:09

LAWRENCEVILLE, N.J., Feb. 5, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that Zheijang HISUN Pharmaceutical Company (HISUN) does not plan to pursue the exclusive option to license ThermoDox® for the Greater China market. Accordingly, the parties will not enter into the exclusive license agreement, and Celsion will not receive nor will it require any future payment for the option or license, as contemplated in the Exclusive Option Agreement...

Celsion Announces Results of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer

2013-01-31 08:29:54

LAWRENCEVILLE, N.J., Jan. 31, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer. Specifically, Celsion has determined, after conferring with its independent Data Monitoring Committee (DMC) that the HEAT...

Celsion Corporation to Host Conference Call and Webcast on January 31, 2013 at 8:00 AM EST to Present Top-Line Data from its Pivotal Phase III HEAT Study

2013-01-30 16:25:14

LAWRENCEVILLE, N.J., Jan. 30, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it will host a conference call and webcast at 8:00 a.m. Eastern Time on Thursday, January 31, 2013 to present the top-line results from its pivotal Phase III HEAT Study with ThermoDox® in combination with radiofrequency ablation (RFA) in patients with intermediate hepatocellular carcinoma (HCC) versus those patients receiving...

National Hepatitis C Survey Prompts Call for All Canadian Boomers to Get Tested

2013-01-29 08:29:06

Information gaps may be compromising optimal diagnosis and treatment TORONTO, Jan. 29, 2013 /CNW/ - Current realities of chronic hepatitis C in Canada and results of a new national survey of physicians and Canadians on awareness of the liver disease, have prompted the Canadian Liver Foundation (CLF) to urge general practitioners (GPs) to immediately begin recommending a one-time blood test for all adults born between 1945 and 1975. "We know that risk-based testing has not been...

Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Enter Into Technology Development Agreement for ThermoDox® for the Greater China Territory

2013-01-22 08:30:45

LAWRENCEVILLE, N.J. and TAIZHOU CITY, China, Jan. 22, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, and Zhejiang Hisun Pharmaceutical Company Ltd. (SSE Code: 600267), a leading Chinese pharmaceutical company, today announced that they have entered into a technology development agreement for ThermoDox® for the greater China territory. Under the terms of the agreement, Hisun will pay $5 million to Celsion immediately, while...

Innovation Without Borders, at the Heart of Institut Mérieux's Strategy

2013-01-13 16:21:58

LYON, France, January 14, 2013 /PRNewswire/ -- Institut Merieux places innovation at the heart of its development strategy and provides multidisciplinary solutions for the innovative and multifactorial management of certain diseases, including tuberculosis, liver cancer and hepatitis. Through its three companies - bioMerieux, Merieux NutriSciences and Transgene - Institut Merieux's objective is to meet worldwide public health needs, through a global approach that...

ResearchMoz: Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail - Market Research Report

2013-01-09 08:24:04

ALBANY, New York, January 9, 2013 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail ResearchMoz announces that it has published a new study Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage...

Paired CT Scans Catch Chemo-Killing Of Liver Tumors In Real Time

2013-01-01 10:43:08

Immediate feedback shows if chemotherapy worked, or if additional treatment is needed Using two successive pairs of specialized CT scans, a team of Johns Hopkins and Dutch radiologists has produced real-time images of liver tumors dying from direct injection of anticancer drugs into the tumors and their surrounding blood vessels. Within a minute, the images showed whether the targeted chemotherapy did or did not choke off the tumors' blood supply and saved patients a month of worry about...

GRUPO COI First In South America to Order a TrueBeam(TM) System for Treating Cancer with Advanced Image-Guided Radiotherapy and Radiosurgery

2012-12-18 04:20:56

RIO DE JANEIRO, December 18, 2012 /PRNewswire/ -- An advanced radiotherapy treatment system, fully equipped for treating cancer with advanced, image-guided radiotherapy and radiosurgery, has been ordered by Clínicas Oncológicas Integradas (GRUPO COI) for installation at the group's Botafogo site in Rio de Janeiro. The TrueBeam(TM) system, which was designed to treat tumors with great accuracy and speed, is the first to be ordered by a treatment center in South America, and is...